Results 101 to 110 of about 10,605 (184)
ABSTRACT Background Garadacimab, a first‐in‐class, recombinant monoclonal antibody targeting activated FXII, is available in Germany for long‐term prophylaxis (LTP) of hereditary angioedema (HAE) since March 2025. We aimed to examine garadacimab real‐life treatment outcomes at our Berlin Angioedema Center of Reference and Excellence (ACARE), the ...
Markus Magerl +5 more
wiley +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber +3 more
wiley +1 more source
ABSTRACT Physical urticaria is a subtype of chronic inducible urticaria characterized by wheals and/or angioedema triggered by physical stimuli. We report a refractory case of combined localized heat urticaria, delayed solar urticaria, and symptomatic dermographism in a 16‐year‐old girl.
Shuta Yoshitani +2 more
wiley +1 more source
ABSTRACT Mucosal surfaces are sites of highly dynamic interactions among epithelial and immune cells, environmental exposures, particularly dietary inputs, and the diverse microbial communities and their metabolites. These elements continually influence each other to maintain homeostasis and ensure appropriate immune discrimination between pathogens ...
Clara Delaroque +5 more
wiley +1 more source
The role of omalizumab in the treatment of adults with severe allergic asthma
Backg round: Omalizumab is a recombinant humanized anti-IgE antibody. It has been used in the treatment of severe allergic asthma since 2007 in Slovenija.
Sabina Škrgat Kristan
doaj
Background and Purpose Aspergillus fumigatus (A. fumigatus) exposure causes of severe allergic asthma, characterized by airway inflammation and epithelial dysfunction. TMBIM6 (Bax inhibitor‐1) has been implicated in airway epithelial stress responses and AKT signalling.
Young‐Jin Yu +7 more
wiley +1 more source
OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION
Antibodies to IgE are a totally new class of medications currently used to enhance the supervision over severe persistent atopic bronchial asthma. Omalizumab is the most well studied, first and only medication of this group, which is recommended for the ...
T.V. Kulichenko
doaj
Chronic Spontaneous Urticaria and Psychiatric Symptoms: The Blood–Brain Barrier Hypothesis
ABSTRACT Chronic spontaneous urticaria (CSU) is a mast cell‐driven inflammatory disease frequently accompanied by anxiety, depression, sleep disturbance, fatigue, and impaired quality of life. Pruritus, disturbed sleep, psychosocial burden, and treatment‐related effects are established contributors to this neuropsychiatric and functional burden ...
Gerasimos N. Konstantinou +4 more
wiley +1 more source
Personalized CSU care guided by CH50. ABSTRACT Background Chronic spontaneous urticaria (CSU) is frequently refractory to guideline‐based therapy, highlighting the need for predictive biomarkers. Dysregulation of the complement system has been implicated in CSU severity, but global complement activity has not been systematically evaluated.
Nidia Planella‐Fontanillas +9 more
wiley +1 more source

